// App-Quantinova.ai

5552 : BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism

Researchers

Presenter

  • Kristen Hurov

Principal Investigators

  • Punit Upadhyaya

  • Johanna Lahdenranta

  • Jessica Kublin

  • Jun Ma

  • Elizabeth Repash

  • Marianna Kleyman

  • Julia Kristensson

  • Liuhong Chen

  • Eric Haines

  • Sailaja Battula

  • Kevin McDonnell

  • Nicholas Keen

Medical Centers

  • Quiet Therapeutics, Lexington, MA.

  • Bicycle Therapeutics Ltd, Cambridge, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Natural Killer cells

  • Nectin Cell Adhesion Molecule 4

  • Peripheral blood mononuclear cell

  • erb-b2 receptor tyrosine kinase 2

  • Interferon-gamma

  • Interleukin-2

Drug/Treatment

  • Urelumab

  • Interferon Gamma

  • Interleukin

  • Interferon

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved